VT

Viatris IncNASDAQ VTRS Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

14.107

Large

Exchange

XNAS - Nasdaq

VTRS Stock Analysis

VT

Uncovered

Viatris Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-1/100

Low score

Market cap $B

14.107

Dividend yield

4.10 %

Shares outstanding

1 196.81 B

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. The company is headquartered in Canonsburg, Pennsylvania and currently employs 37,000 full-time employees. The Company’s segments include Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries within various markets and economies, as well as its anti-retroviral franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands, complex generics, and biosimilars. The company operates around 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its Viatris Eye Care division is focused on discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases.

View Section: Eyestock Rating